SEC Comment Letter for PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075) (PMCB) — Mar 3, 2016
PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)
Date: March 3, 2016 · CIK: 0001157075 · Accession: 0000000000-16-067075
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-68008
Letter
Mail Stop 4720 March 3 , 2016 Via E -mail Mr. Kenneth Waggoner Chief Executive Officer, Chairman of the Board and Director PharmaCyte Biotech, Inc. 12510 Prosperity Drive, Suite 310 Silver Spring, MD 20904
Re: PharmaCyte Biotech, Inc. Form 10 -K for the Fiscal Year Ended April 30, 2015 Filed July 29, 2015 and amended on January 19, 2016 and March 2, 2016 File No. 333-68008
Dear Mr. Waggoner :
We have comp leted our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiat ed by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Sec urities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Sharon Blume
Show Raw Text
Mail Stop 4720 March 3 , 2016 Via E -mail Mr. Kenneth Waggoner Chief Executive Officer, Chairman of the Board and Director PharmaCyte Biotech, Inc. 12510 Prosperity Drive, Suite 310 Silver Spring, MD 20904 Re: PharmaCyte Biotech, Inc. Form 10 -K for the Fiscal Year Ended April 30, 2015 Filed July 29, 2015 and amended on January 19, 2016 and March 2, 2016 File No. 333-68008 Dear Mr. Waggoner : We have comp leted our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiat ed by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Sec urities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Sharon Blume Sharon Blume Accounting Branch Chief Office of Healthcare and Insurance